Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

Documenti analoghi

• Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
  di: Elisabetta Antonioli, et al.
  Pubblicazione: (2010-08-01)
• Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden
  di: Ilana Renault Zalcberg, et al.
  Pubblicazione: (2011-03-01)
• Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
  di: Kittitat Chiaranairungrot, et al.
  Pubblicazione: (2022-12-01)
• Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
  di: Richard T. Silver, et al.
  Pubblicazione: (2019-11-01)
• Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
  di: Guido Finazzi, et al.
  Pubblicazione: (2007-01-01)